Import from '@womanrx/components'

Norethindrone Metabolism and Energy Expenditure: What Every Woman Should Know

What Norethindrone Actually Is (and How It Differs From Progesterone)

Norethindrone is a synthetic 19-nortestosterone derivative, not a copy of the progesterone your ovaries make. That structural difference matters enormously for metabolism. Natural progesterone binds almost exclusively to the progesterone receptor (PR) and has mild thermogenic properties via a 0.3-0.5 °C rise in basal body temperature in the luteal phase. Norethindrone binds the PR effectively, but it also carries partial androgen-receptor (AR) agonism and weak glucocorticoid-receptor (GR) cross-talk. Both of these off-target actions shape how your body handles fuel.

Norethindrone acetate (NETA), sold as Aygestin and the progestin component of Activella and FemHRT among others, is a prodrug. After you swallow it, intestinal and hepatic esterases cleave the acetate group and you circulate norethindrone. So the metabolic conversation always comes back to NET.

Oral Bioavailability and First-Pass Kinetics in Women

Net oral bioavailability of norethindrone is approximately 64%, with wide inter-individual variability driven by CYP3A4 activity in the gut wall and liver. Body fat percentage influences the volume of distribution; women with higher adiposity may see prolonged half-lives because NET is lipophilic and partitions into fat tissue. The elimination half-life is roughly 8 hours, which is why contraceptive mini-pill regimens require consistent daily timing.

Ethinyl estradiol co-administration (as in combined oral contraceptives) raises norethindrone exposure by about 30-40% by competing for CYP3A4. If you switch from a combined pill to the progestin-only pill, the effective dose your tissues see actually drops, even at the same labeled dose.

SHBG: The Hidden Metabolic Lever

Norethindrone suppresses sex hormone-binding globulin (SHBG) more than most progestins because of its androgenic activity. Lower SHBG means more free testosterone circulates. For women already on the hyperandrogenic end (PCOS, adrenal hyperplasia), this can worsen insulin resistance and shift substrate oxidation away from fat. For postmenopausal women on MHT who already have low SHBG, the clinical magnitude is smaller but still worth tracking.

How Norethindrone Affects Your Resting Metabolic Rate

The thermogenic story of progestins is nuanced. Natural progesterone raises your core temperature and, with it, oxygen consumption. Norethindrone does not reliably replicate this effect and may actually blunt it.

The Thermogenesis Comparison: NET vs. Natural Progesterone

Progesterone's thermogenic action is mediated through central (hypothalamic) mechanisms. A well-designed crossover study measuring 24-hour energy expenditure in women found that oral micronized progesterone increased 24-hour EE by roughly 4-5% compared to placebo, corresponding to approximately 100 kcal/day. Norethindrone does not appear to replicate this. Its AR partial agonism may instead redirect energy towards protein anabolism and glycogen storage, a pattern more consistent with androgenic steroids than with thermogenic progestogens.

The WomanRx clinical framework for progestin metabolic profiling categorizes synthetic progestins into three metabolic phenotypes:

1. Thermogenic-neutral: Micronized progesterone, dydrogesterone. These preserve or mildly raise REE through central thermogenesis with minimal SHBG or AR impact.
2. Androgenic-metabolic: Norethindrone, levonorgestrel, tibolone. AR partial agonism, SHBG suppression, possible insulin resistance amplification, no central thermogenesis.
3. Metabolically favorable: Drospirenone, dienogest. Anti-androgenic, SHBG-neutral or raising, may improve insulin sensitivity.

Norethindrone sits firmly in phenotype 2. This does not make it a bad drug. It makes it a drug whose metabolic trade-offs deserve explicit discussion with your clinician.

Substrate Oxidation: What Fuel Does Your Body Burn on NET?

Substrate oxidation studies, meaning indirect calorimetry experiments measuring the respiratory quotient (RQ), suggest that androgenic progestins shift oxidation toward carbohydrate and away from fat. A higher RQ (approaching 1.0) indicates carbohydrate burning; a lower RQ (approaching 0.7) indicates fat burning. Natural progesterone tends to lower RQ slightly during the luteal phase, encouraging fat oxidation. Androgenic progestins may do the opposite, though direct NET-specific calorimetry data in women are limited (see the evidence-gap discussion below).

Clinically, this matters most for women managing their weight alongside a condition that requires NET: heavy menstrual bleeding (HMB), endometriosis, or as part of MHT.

Norethindrone and Insulin Sensitivity

Insulin resistance is the metabolic thread connecting PCOS, perimenopausal weight gain, and type 2 diabetes risk. Where does norethindrone sit in that story?

Evidence in Women With PCOS

PCOS already involves androgen excess and insulin resistance. Adding a progestin with partial AR agonism is not automatically a problem, but the dose matters. At contraceptive mini-pill doses (0.35 mg/day), the androgenic load is low and clinical insulin-sensitivity changes are generally not statistically significant in small trials. At the 5 mg/day dose used for endometriosis or HMB, androgenic effects are more pronounced, and women with pre-existing insulin resistance should be monitored with fasting glucose and HbA1c at baseline and 6-12 months.

For women with PCOS who need a progestin for cycle regulation or endometrial protection, ACOG recommends considering the androgenic profile of the chosen progestin, with lower-androgen options preferred when metabolic risk is already elevated.

Perimenopausal Women on MHT

Women entering perimenopause experience a natural decline in estrogen that redistributes fat toward visceral depots and worsens insulin sensitivity independent of any medication. When norethindrone (as NETA) is added to estradiol in MHT, the combination's net metabolic effect depends on which hormone wins the tug of war. Estradiol is generally metabolically protective, improving insulin sensitivity and visceral fat distribution. NETA at doses of 0.5-1 mg/day (as in standard continuous combined MHT) appears to partially attenuate estradiol's favorable effect on insulin sensitivity, though the clinical magnitude in healthy perimenopausal women is modest.

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions), published in JAMA, compared five MHT regimens and found that the estrogen-plus-MPA arm had the worst HDL effect; norethindrone-containing arms were not separately isolated in that trial, but subsequent analyses of European MHT data confirm that NETA at 0.5 mg/day has a smaller adverse lipid impact than MPA at 2.5 mg/day, while still not matching the neutral or favorable profile of micronized progesterone.

Glucose Metabolism Numbers to Know

• Fasting insulin: increases of approximately 10-15% have been reported with NETA 1 mg/day added to oral estradiol, compared to estradiol alone, in 12-week crossover studies.
• HOMA-IR: small but statistically significant rises versus natural progesterone comparators in some trials.
• HbA1c: no clinically significant changes at standard MHT doses in women without pre-existing diabetes in trials up to 12 months.

The clinical bottom line: if you have type 2 diabetes or insulin resistance and need MHT, discuss whether micronized progesterone or a low-androgen progestin such as drospirenone would better preserve your metabolic gains from estradiol.

Norethindrone for Heavy Menstrual Bleeding: Does the Metabolic Profile Change Anything?

For HMB, norethindrone is prescribed at 5 mg two to three times daily (15 mg/day total) for 10-21 days per cycle, or continuously at lower doses. At these higher doses, the androgenic and metabolic effects are more clinically relevant than at contraceptive doses.

A 2013 Cochrane review of progestins for HMB found that norethindrone significantly reduced menstrual blood loss compared to placebo, but that the levonorgestrel-releasing intrauterine system (LNG-IUS) outperformed oral progestins in reducing blood loss and improving quality of life. The review also noted that oral progestins, including norethindrone, had higher rates of side effects including weight gain and mood changes compared to the LNG-IUS, where systemic absorption is minimal.

Weight gain on oral norethindrone for HMB is reported in roughly 20-30% of women in observational studies, though controlled-trial estimates are lower. Whether this reflects true fat gain, fluid retention from partial mineralocorticoid activity, or appetite stimulation from androgenic signaling is not fully separated in published data. It is probably all three to varying degrees.

Dosing Across Life Stage for HMB

| Life Stage | Typical NET Dose for HMB | Metabolic Watch-Point | |---|---|---| | Reproductive years (cycling) | 5 mg 3x/day, days 5-26 | Monitor weight, fasting glucose if BMI >30 or PCOS | | Perimenopause | 5 mg/day continuously or cyclically | Visceral fat, lipid panel, BP at 6 months | | Postmenopause | Rarely used for HMB alone; low-dose NETA in MHT combos | Focus on lipid profile and insulin sensitivity |

Endometriosis: Long-Term Norethindrone at 5 mg/day and Metabolic Monitoring

Norethindrone acetate 5 mg/day is FDA-approved for endometriosis and is one of the most cost-effective hormonal options available. Treatment can extend for years. That time horizon amplifies even modest metabolic effects.

What to Monitor on Long-Term NETA for Endometriosis

• Lipids: NETA at 5 mg/day can reduce HDL cholesterol by 10-15% and raise LDL by 5-10% over 6-12 months in some studies, primarily through its androgenic suppression of hepatic lipase. Get a fasting lipid panel at baseline, 6 months, and annually.
• Bone density: Endometriosis itself and GnRH agonist co-therapy suppress estrogen, putting bone at risk. NETA has some residual estrogenic activity at bone (it converts partially to ethinyl estradiol in vivo), providing a degree of bone-protective effect, which is one reason it is sometimes preferred over GnRH agonist monotherapy.
• Acne and hirsutism: Androgenic side effects are among the most common reasons women discontinue. Document baseline Ferriman-Gallwey score and skin status.
• Body weight: Expect a possible gain of 1-3 kg over the first 6 months; counsel on the likely mechanism (fluid, appetite, not pure fat accretion) and refer to dietetics if clinically significant.

Pregnancy, Lactation, and Contraception Requirements

Norethindrone is CONTRAINDICATED in confirmed pregnancy. This is not a soft contraindication. The drug labeling carries a black-box-adjacent warning because early data on 19-nortestosterone progestins suggested possible virilization of female fetuses exposed in the first trimester. While later epidemiological data from the Collaborative Perinatal Project modestly attenuated this concern at low doses, the FDA pregnancy category was X for the acetate formulation. No safe dose in pregnancy has been established.

If You Are Trying to Conceive

Stop norethindrone before attempting conception. Unlike depot medroxyprogesterone acetate (which can delay return of ovulation for 6-18 months), norethindrone's ovulation suppression reverses within 1-3 months of stopping. For the progestin-only mini-pill, ovulation returns within 2-4 weeks in most women. Fertility itself is not permanently impaired.

If You Are Using Norethindrone for Non-Contraceptive Indications

Women prescribed norethindrone for HMB or endometriosis who are not surgically sterile must use reliable contraception concurrently if pregnancy is possible. At therapeutic doses of 5 mg/day, norethindrone does suppress ovulation in most but not all cycles; it is not a reliable contraceptive at this dosing pattern. Your clinician may add a barrier method, IUD, or recommend confirmation of anovulation via progesterone levels.

Lactation

Norethindrone passes into breast milk in small amounts, estimated at 0.1-0.2% of the maternal dose. The American Academy of Pediatrics classifies progestin-only contraceptives, including the norethindrone mini-pill, as compatible with breastfeeding. The theoretical concern about androgenic effects on a breastfed infant at these trace levels is not supported by clinical outcome data. The norethindrone mini-pill (0.35 mg/day) is, in fact, the preferred hormonal contraceptive for breastfeeding women because it does not suppress milk supply the way combined estrogen-progestin pills can in the early postpartum period.

Postpartum Timing

If you are postpartum and not breastfeeding, the progestin-only pill can be started immediately. If breastfeeding, most guidelines, including ACOG's postpartum contraception guidance, support starting progestin-only contraception at hospital discharge or within the first 6 weeks without waiting, given the low risk and high contraceptive benefit.

Who Norethindrone Is Right For (and Who Should Think Twice)

Women Who Are Good Candidates

• Women with HMB who need a low-cost, widely available oral option and who do not have baseline insulin resistance or significant androgenic symptoms.
• Women with endometriosis who have failed or cannot tolerate GnRH agonists and for whom the bone-protective partial estrogenicity of NET is a benefit.
• Breastfeeding women needing reliable hormonal contraception without estrogen.
• Postmenopausal women on MHT where low-dose NETA (0.5-1 mg/day) paired with estradiol provides endometrial protection at a relatively modest metabolic cost compared to higher-androgen progestins.

Women Who Should Discuss Alternatives First

• Women with PCOS and insulin resistance: the androgenic load of NET may worsen the metabolic picture. Drospirenone-containing pills or levonorgestrel IUS (minimal systemic absorption) are worth discussing.
• Women with significantly elevated cardiovascular risk or dyslipidemia: NET's HDL-lowering potential is a real consideration at doses of 5 mg/day.
• Women with a history of androgenic side effects (acne, hirsutism, weight gain) on prior progestin-only pills: they are likely sensitive to AR agonism and may do better with a less androgenic agent.
• Women actively attempting pregnancy: stop NET and confirm ovulatory return before insemination.
• Perimenopausal women already managing visceral adiposity and insulin resistance: micronized progesterone 100-200 mg/day or dydrogesterone provides endometrial protection with a more metabolically neutral profile. The IMS (International Menopause Society) 2020 recommendations explicitly favor micronized progesterone in women with metabolic risk factors.

The Evidence Gap: What We Do Not Yet Know About Norethindrone in Women

Women have been consistently under-represented in metabolic pharmacology trials. Most calorimetry studies examining progestin effects on resting energy expenditure have been conducted in small cohorts, often fewer than 30 women, and rarely stratify by menopausal status, PCOS diagnosis, or ethnicity, all of which influence baseline insulin sensitivity and body composition.

Specifically, what the literature is missing:

• Indirect calorimetry RCTs comparing NET to micronized progesterone in women with PCOS. No such trial with adequate power exists as of this writing.
• Longitudinal body composition data (DEXA scan) in premenopausal women on NET 5 mg/day for endometriosis beyond 12 months.
• Continuous glucose monitoring data on NET's real-world glycemic variability in women with prediabetes.
• Pharmacogenomic data on which CYP3A4 or AR polymorphisms predict metabolic sensitivity to norethindrone.

The substrate-oxidation and thermogenesis claims above are supported by mechanistic and comparative data from natural progesterone versus androgenic-progestin trials, but direct NET-specific calorimetry trials in adequately powered women-only samples do not yet exist. Your clinician should know you are asking the right questions even when the literature has not caught up.

Practical Monitoring Plan for Women on Norethindrone

Here is a concrete monitoring schedule to discuss with your prescriber, organized by indication and dose:

Contraceptive Dose (0.35 mg/day)

• Baseline: weight, BP.
• Annual: weight, BP, symptom review (acne, mood, libido).
• No routine metabolic labs needed unless symptoms or risk factors emerge.

HMB or Endometriosis Dose (5 mg/day)

• Baseline: weight, fasting lipid panel, fasting glucose or HbA1c if BMI >30 or PCOS, BP, Ferriman-Gallwey score.
• 3 months: symptom review, weight, BP.
• 6 months: repeat lipid panel and fasting glucose, weight, bone density discussion if co-treating with GnRH agonist.
• Annually: full metabolic panel, DEXA if on GnRH agonist add-back or if treatment has continued beyond 2 years.

MHT Combination Dose (0.5-1 mg NETA/day)

• Baseline: fasting lipid panel, weight, BP.
• 3-6 months: symptom review, BP, weight.
• Annually: lipid panel, fasting glucose, mammography per standard screening guidelines.

If your LDL rises >20% from baseline or your fasting glucose crosses into impaired range (>100 mg/dL), a progestin switch conversation is warranted. You do not have to accept a drug's metabolic side effects if an alternative serves your underlying condition equally well.

The Menopause Society's 2023 position statement states: "The type, dose, and route of administration of progestogen may affect the risk-benefit profile, and individualization is encouraged." That is clinical permission to have exactly this conversation.